The effect of ethylenediaminetetramethylenephosphonate on the biodistribution of tumor-seeking radionuclides
Schomäcker, K.; Franke, W.G.; Mäding, P.; Shukla, S.K.; Weiss, S.; Limouris, G.S.; Jantsch, K.
Nuklearmedizin. Nuclear Medicine 32(1): 23-26
1993
ISSN/ISBN: 0029-5566 PMID: 8464756 Document Number: 417334
It is well known that after application of radioactive complexes for tumour diagnosis or therapy, such as 67Ga-citrate or radiolanthanide complexes (167Tm- or 169Yb-nitrilotriacetate, -citrate, -alpha-hydroxyisobutyrate, 90Y-citrate, etc.) activity is accumulated not only in the tumour but also in other organs, above all liver and bone. This is the main obstacle to their medical use. Recently published results encouraged us to use ethylenediaminetetramethylene phosphonate (EDTMP) for the reduction of extratumoural liver activity. The results show that even small amounts of EDTMP (1-2 mg/kg BW) reduce the activity deposition in the liver by about one order of magnitude. EDTMP provoked elimination of activity from tumour, skeleton and other tissues but not to the same extent as from the liver. Tumor/liver activity ratios > 5 are achievable in this manner.